News
NHS Cancer Treatment Rates Highest Ever Recorded In 2022
The NHS has released encouraging statistics regarding cancer rates in the UK to kick off the new year. Over the past year, more patients than ever before the pandemic received essential NHS cancer treatments. Furthermore, the number of people...
Drug Research
Antibiotic Resistance Being Weakened By Persistent Bacteria
Researchers from Uppsala University in Sweden have released a study on how various antibiotic treatments affect different types of bacteria and how they respond to such treatments. The study's findings highlight the need for rigorously following antibiotic prescription instructions.
According...
Clinical Trials
CardieX Subsidiary ATCOR Partners with Invaryant to Enable Clinical Trials with Advanced New AI Medical Technology
CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that empowers individuals with precision AI to...
News
Japan’s MHLW approves AstraZeneca’s Imfinzi, Imjudo for liver, lung cancers
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved AstraZeneca’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) to treat advanced liver, biliary tract, and lung cancers.
The combination of Imfinzi and Imjudo has been approved to treat unresectable hepatocellular...
News
Cellectis, Primera partner for mitochondrial disease gene therapies
Cellectis has entered into a strategic collaboration agreement with Primera Therapeutics to develop a gene editing platform to treat mitochondrial diseases.
Primera Therapeutics is launched by Mayflower Bioventures, a cell and gene therapy accelerator stood up from Hibiscus BioVentures and...
News
BDR Pharma launches first generic apalutamide to treat prostate cancer in India
BDR Pharmaceutical has launched the first generic apalutamide in India to treat both metastatic castration sensitive prostate cancer as well as non-metastatic castration resistant prostate cancer.
The product will be available across India and shall be of 60 mg strength...
Drug Research
Alligator and Orion expand immuno-oncology research alliance
Alligator Bioscience has expanded its research collaboration and license agreement with Orion Corp., a global pharmaceutical company based in Finland, to discover and develop new bispecific antibody cancer therapeutics.
The collaboration has been expanded to add the development of a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read